# FDA Approves Wegovy for MASH Treatment: A Game-Changer for Liver Disease

Discover how Wegovy, Novo Nordisk's weight management drug, received FDA approval for treating MASH (metabolic dysfunction-associated steatohepatitis) in adults with moderate to advanced liver fibrosis. Host Alexandra Reeves breaks down this groundbreaking development that transforms Wegovy from a weight loss medication into a powerful treatment for chronic liver disease. Learn about the impressive clinical trial results showing 63% MASH resolution rate compared to just 34% with placebo, and how this approval creates a $50 billion market opportunity. The episode explores Novo Nordisk's strategic expansion of semaglutide applications, potential oral formulations on the horizon, competitor responses, and the profound impact this has on millions suffering from this previously difficult-to-treat condition. Essential listening for anyone interested in pharmaceutical breakthroughs, chronic disease management, or investment opportunities in healthcare innovation.

Some great Deals https://amzn.to/49SJ3Qs

For more check out http://www.quietplease.ai

單集識別碼：1000722213464

GUID：https://api.spreaker.com/episode/67391635

發佈日期：2025/8/17 上午1:23:46